Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,120.00
Ask: 12,124.00
Change: 68.00 (0.56%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday preview: US jobless claims, AstraZeneca in the spotlight

Wed, 10th Feb 2021 18:52

(Sharecast News) - The economic calendar on Thursday will be exceedingly light with a reading on weekly US unemployment claims the only event that might easily move markets.



Consensus is expecting but a slight drop in the number of initial jobless claims from 779,000 for the week before to 769,000.

A speech from European Central Bank vice-president, Luis De Guindos, will also be worth monitoring.

No major economic releases are scheduled in the UK.

Further afield, rate-setters in Manila are due to meet to decide on policy.



For AstraZeneca's fourth quarter, UBS analyst Michael Leuchten has penciled sales of $7.22bn, putting him slightly ahead of the consensus which is at $7.16bn.

Core operating profits on the other hand were pegged to come in at $1.94bn (consensus: $2.02bn) for earnings per share of $1.04 (consensus: $1.09).

"Top-line momentum remains key for investors," he said, adding that he expected investors to focus their questions on the outfit's business in China, which accounts for approximately a fifth of its sales.

The analyst also broke down his sales forecasts for AstraZeneca's key treatments: Tagrisso ($1.15bn), Lynparza ($483m), Imfinzi ($532m) and Calquence ($157m).

Going forwards, Leuchten expected AstraZeneca would guide towards single-digit topline growth - excluding vaccines - and for mid-to-high teens growth in earnings per share, with the latter not including gains from the spin-out of Viela.

Thursday 11 February

INTERIMS

MJ Gleeson

INTERIM EX-DIVIDEND DATE

Hargreaves Lansdown, Henderson Smaller Companies Inv Trust, PZ Cussons, The Mission Group

QUARTERLY EX-DIVIDEND DATE

BMO Commercial Property Trust Limited, Chenavari Toro Income Fund Limited NPV, Custodian Reit , ICG Enterprise Trust, The Renewables Infrastructure Group Limited

INTERNATIONAL ECONOMIC ANNOUNCEMENTS

Continuing Claims (US) (13:30)

Initial Jobless Claims (US) (13:30)

Q4

AstraZeneca

GMS

Coral Products, Tesco

FINALS

AstraZeneca, Coca-Cola European Partners (DI), Coca-Cola HBC AG (CDI), Relx plc, Yamana Gold Inc. NPV (CDI)

SPECIAL EX-DIVIDEND DATE

Anglo Asian Mining

EGMS

Glanbia, Law Debenture Corp.

AGMS

Euromoney Institutional Investor

UK ECONOMIC ANNOUNCEMENTS

RICS Housing Market Survey (00:01)

FINAL DIVIDEND PAYMENT DATE

Hargreave Hale AIM VCT , Sage Group, Unicorn AIM VCT

FINAL EX-DIVIDEND DATE

Aberforth Smaller Companies Trust, Avon Rubber, Blackrock Income And Growth Investment Trust, Northamber
More News
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.